Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis plan.
Marie Warrer MunchAnders GranholmS N MyatraBkt VijayaraghavanMaria CronhjortR R WahlinStephan M JakobLuca CioccariMaj-Brit Nørerregaard KjaerGitte Kingo VesterlundTine Sylvest MeyhoffMarie HellebergMorten Hylander MöllerThomas BenfieldBalasubramanian VenkateshNaomi HammondSharon MicallefAbhinav BassiOommen JohnVivekanand JhaK T KristiansenC S UlrikV L JørgensenMargit SmittMorten H BestleA S AndreasenL M PoulsenBodil Steen RasmussenA C BrøchnerThomas StrømAnders MøllerM S KhanAjay PadmanabanJ V DivatiaSanjith SaseedharanKapil BorawakeFarhad KapadiaSubhal DixitRajesh ChawlaUrvi ShuklaPravin AminMichelle S ChewChristian GluudTheis LangeAnders PernerPublished in: Acta anaesthesiologica Scandinavica (2021)
The COVID STEROID 2 trial will provide evidence on the optimal dosing of systemic corticosteroids for COVID-19 patients with severe hypoxia with important implications for patients, their relatives and society.
Keyphrases
- sars cov
- coronavirus disease
- end stage renal disease
- study protocol
- clinical trial
- phase iii
- newly diagnosed
- randomized controlled trial
- ejection fraction
- early onset
- chronic kidney disease
- endothelial cells
- phase ii
- peritoneal dialysis
- respiratory syndrome coronavirus
- high dose
- drug induced
- patient reported outcomes
- patient reported